UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dark matter in the inert doublet model after the discovery of a Higgs-like boson at the LHC

The journal of high energy physics, 2013-09, Vol.2013 (9), p.1-35, Article 106

2013

Volltextzugriff (PDF)

Interpreting the LHC Higgs search results in the MSSM

Physics letters. B, 2012-03, Vol.710 (1), p.201-206

2012

Volltextzugriff (PDF)

Prospects for charged Higgs searches at the LHC

The European physical journal. C, Particles and fields, 2017-05, Vol.77 (5), p.1-33, Article 276

2017

Volltextzugriff (PDF)

Flavor constraints on two-Higgs-doublet models with general diagonal Yukawa couplings

Physical review. D, 2010-02, Vol.81 (3), p.035016, Article 035016

2010

Volltextzugriff (PDF)

Status of the charged Higgs boson in two Higgs doublet models

The European physical journal. C, Particles and fields, 2018-03, Vol.78 (3), p.1-22, Article 182

2018

Volltextzugriff (PDF)

Confronting the MSSM and the NMSSM with the discovery of a signal in the two photon channel at the LHC

The European physical journal. C, Particles and fields, 2012-10, Vol.72 (10), p.1-23, Article 2171

2012

Volltextzugriff (PDF)

Improved prediction for the mass of the W boson in the NMSSM

The journal of high energy physics, 2015-09, Vol.2015 (9), p.1-47, Article 158

2015

Volltextzugriff (PDF)

MSSM Higgs boson searches at the LHC: benchmark scenarios after the discovery of a Higgs-like particle

The European physical journal. C, Particles and fields, 2013-09, Vol.73 (9), p.1-20, Article 2552

2013

Volltextzugriff (PDF)

Light Higgs bosons in phenomenological NMSSM

The European physical journal. C, Particles and fields, 2011-04, Vol.71 (4), p.1-22, Article 1608

2011

Volltextzugriff (PDF)

Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial

European journal of cancer (1990), 2019-03, Vol.110, p.53-61

2019

Volltextzugriff (PDF)

Defining the human copper proteome and analysis of its expression variation in cancers

Metallomics, 2017, Vol.9 (2), p.112-123

2017

Volltextzugriff (PDF)

MSSM interpretations of the LHC discovery: light or heavy Higgs?

The European physical journal. C, Particles and fields, 2013-04, Vol.73 (4), p.1-23, Article 2354

2013

Volltextzugriff (PDF)

1904 Chromosomal aberrations associated with lymphovascular invasion in breast cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S300-S300

2015

Volltextzugriff (PDF)

AIB1 is a predictive factor for tamoxifen response in premenopausal women

Annals of oncology, 2010-02, Vol.21 (2), p.238-244

2010

Volltextzugriff (PDF)

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

British journal of cancer, 2011-05, Vol.104 (11), p.1762-1769

2011

Volltextzugriff (PDF)

Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer

The Journal of pathology, 2009-02, Vol.217 (3), p.372-379

2009

Volltextzugriff (PDF)

Prospects for lunar satellite detection of radio pulses from ultrahigh energy neutrinos interacting with the moon

Physical review letters, 2007-02, Vol.98 (7), p.071103-071103, Article 071103

2007

Volltextzugriff (PDF)

Proliferative responses to altered 17β-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors

Endocrine-related cancer, 2006-09, Vol.13 (3), p.875-884

2006

Volltextzugriff (PDF)

1812 Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival. Retrospective analyses of the STO3 randomizedtrial

European journal of cancer (1990), 2015-09, Vol.51, p.S269-S269

2015

Volltextzugriff (PDF)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

Breast cancer research and treatment, 2016-11, Vol.160 (2), p.313-322

2016

Volltextzugriff (PDF)

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

Journal of clinical oncology, 2022-12, Vol.40 (35), p.4071-4082

2022

Volltextzugriff (PDF)

300P Gene expression landscape of the long-term tamoxifen resistance in premenopausal ER+ breast cancer patients in the STO-5 controlled randomized clinical trial with >20-year follow-up

Annals of oncology, 2024-09, Vol.35, p.S340-S340

2024

Volltextzugriff (PDF)

409P Biological tumor traits predicting late recurrence in premenopausal breast cancer patients: Insights from the STO-5 trial with 20-year follow-up

Annals of oncology, 2024-09, Vol.35, p.S390-S390

2024

Volltextzugriff (PDF)

316P Differential long-term benefit of 2-year adjuvant tamoxifen therapy for luminal-type breast cancer: Insights from a 20-year follow-up analysis of the STO trials

Annals of oncology, 2024-09, Vol.35, p.S346-S346

2024

Volltextzugriff (PDF)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Breast cancer research : BCR, 2005-01, Vol.7 (3), p.R284-R290, Article R284

2005

Volltextzugriff (PDF)

1 – 25 von 278

Suche als RSS-Feed

Aktive Filter

ThemaBiological And Medical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(238)
Mit Volltextzugriff
(262)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Dark matter in the inert doublet model after the discovery of a Higgs-like boson at the LHC

Interpreting the LHC Higgs search results in the MSSM

Prospects for charged Higgs searches at the LHC

Flavor constraints on two-Higgs-doublet models with general diagonal Yukawa couplings

Status of the charged Higgs boson in two Higgs doublet models

Confronting the MSSM and the NMSSM with the discovery of a signal in the two photon channel at the LHC

Improved prediction for the mass of the W boson in the NMSSM

MSSM Higgs boson searches at the LHC: benchmark scenarios after the discovery of a Higgs-like particle

Light Higgs bosons in phenomenological NMSSM

Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial

Defining the human copper proteome and analysis of its expression variation in cancers

MSSM interpretations of the LHC discovery: light or heavy Higgs?

1904 Chromosomal aberrations associated with lymphovascular invasion in breast cancer

AIB1 is a predictive factor for tamoxifen response in premenopausal women

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer

Prospects for lunar satellite detection of radio pulses from ultrahigh energy neutrinos interacting with the moon

Proliferative responses to altered 17β-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors

1812 Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival. Retrospective analyses of the STO3 randomizedtrial

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

300P Gene expression landscape of the long-term tamoxifen resistance in premenopausal ER+ breast cancer patients in the STO-5 controlled randomized clinical trial with >20-year follow-up

409P Biological tumor traits predicting late recurrence in premenopausal breast cancer patients: Insights from the STO-5 trial with 20-year follow-up

316P Differential long-term benefit of 2-year adjuvant tamoxifen therapy for luminal-type breast cancer: Insights from a 20-year follow-up analysis of the STO trials

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Aktive Filter

Suchergebnisse filtern